Cyhoeddiad
2024
- Ng, B. et al. 2024. Tau depletion in human neurons mitigates Aβ-driven toxicity. Molecular Psychiatry 29, pp. 2009-2020. (10.1038/s41380-024-02463-2)
2023
- Beccano-Kelly, D. A. et al. 2023. Calcium dysregulation combined with mitochondrial failure and electrophysiological maturity converge in Parkinson’s iPSC-dopamine neurons. iScience 26(7), article number: 107044. (10.1016/j.isci.2023.107044)
2022
- Burley, S., Beccano-Kelly, D. A., Talbot, K., Llana, O. C. and Wade-Martins, R. 2022. Hyperexcitability in young iPSC-derived C9ORF72 mutant motor neurons is associated with increased intracellular calcium release. Scientific Reports 12(1), article number: 7378. (10.1038/s41598-022-09751-3)
2020
- Mancini, A. et al. 2020. From synaptic dysfunction to neuroprotective strategies in genetic Parkinson’s disease: lessons from LRRK2. Frontiers in Cellular Neuroscience 14 (10.3389/fncel.2020.00158)
2019
- Überbacher, C. et al. 2019. Application of CRISPR/Cas9 editing and digital droplet PCR in human iPSCs to generate novel knock-in reporter lines to visualize dopaminergic neurons. Stem Cell Research 41 (10.1016/j.scr.2019.101656)
- Benkert, J. et al. 2019. Cav2.3 channels contribute to dopaminergic neuron loss in a model of Parkinson’s disease. Nature Communications 10(1) (10.1038/s41467-019-12834-x)
2015
- Volta, M. et al. 2015. Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release.. Parkinsonism & Related Disorders 21(10), pp. 1156-1163. (10.1016/j.parkreldis.2015.07.025)
2014
- Munsie, L. N. et al. 2014. Retromer-dependent neurotransmitter receptor trafficking to synapses is altered by the Parkinson's disease VPS35 mutation p.D620N.. Human Molecular Genetics 24(6), pp. 1691-1703. (10.1093/hmg/ddu582)
- Beccano-Kelly, D. A. et al. 2014. LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory.. Human Molecular Genetics 24(5), pp. 1336-1349. (10.1093/hmg/ddu543)
- Beccano-Kelly, D. A. et al. 2014. Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice.. Frontiers in Cellular Neuroscience (10.3389/fncel.2014.00301)
- Vilarino-Guell, C. et al. 2014. DNAJC13 mutations in Parkinson disease.. Human Molecular Genetics 23(7), pp. 1794-1801. (10.1093/hmg/ddt570)
- Brigidi, G. S. et al. 2014. Palmitoylation of δ-catenin by DHHC5 mediates activity-induced synapse plasticity.. Nature Neuroscience 17(4), pp. 522-532. (10.1038/nn.3657)
- Walker, M. D. et al. 2014. Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging. Journal of Parkinson{'}s disease 4(3), pp. 483-498. (10.3233/JPD-140344)
2012
- Doherty, G. H., Beccano-Kelly, D., Yan, S. D., Gunn-Moore, F. J. and Harvey, J. 2012. Leptin prevents hippocampal synaptic disruption and neuronal cell death induced by amyloid β.. Neurobiology of Aging 34(1), pp. 226-237. (10.1016/j.neurobiolaging.2012.08.003)
- Beccano-Kelly, D. and Harvey, J. 2012. Leptin: a novel therapeutic target in Alzheimer's disease?. International Journal of Alzheimer’s Disease 2012, article number: 594137. (10.1155/2012/594137)
2009
- Milligan, C. J. et al. 2009. Robotic multiwell planar patch-clamp for native and primary mammalian cells.. Nature Protocols 4, pp. 244-255. (10.1038/nprot.2008.230)
2006
- Josephs, K. A. et al. 2006. Atypical progressive supranuclear palsy with corticospinal tract degeneration.. Journal of Neuropathology and Experimental Neurology 65(4), pp. 396-405. (10.1097/01.jnen.0000218446.38158.61)
Erthyglau
- Ng, B. et al. 2024. Tau depletion in human neurons mitigates Aβ-driven toxicity. Molecular Psychiatry 29, pp. 2009-2020. (10.1038/s41380-024-02463-2)
- Beccano-Kelly, D. A. et al. 2023. Calcium dysregulation combined with mitochondrial failure and electrophysiological maturity converge in Parkinson’s iPSC-dopamine neurons. iScience 26(7), article number: 107044. (10.1016/j.isci.2023.107044)
- Burley, S., Beccano-Kelly, D. A., Talbot, K., Llana, O. C. and Wade-Martins, R. 2022. Hyperexcitability in young iPSC-derived C9ORF72 mutant motor neurons is associated with increased intracellular calcium release. Scientific Reports 12(1), article number: 7378. (10.1038/s41598-022-09751-3)
- Mancini, A. et al. 2020. From synaptic dysfunction to neuroprotective strategies in genetic Parkinson’s disease: lessons from LRRK2. Frontiers in Cellular Neuroscience 14 (10.3389/fncel.2020.00158)
- Überbacher, C. et al. 2019. Application of CRISPR/Cas9 editing and digital droplet PCR in human iPSCs to generate novel knock-in reporter lines to visualize dopaminergic neurons. Stem Cell Research 41 (10.1016/j.scr.2019.101656)
- Benkert, J. et al. 2019. Cav2.3 channels contribute to dopaminergic neuron loss in a model of Parkinson’s disease. Nature Communications 10(1) (10.1038/s41467-019-12834-x)
- Volta, M. et al. 2015. Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release.. Parkinsonism & Related Disorders 21(10), pp. 1156-1163. (10.1016/j.parkreldis.2015.07.025)
- Munsie, L. N. et al. 2014. Retromer-dependent neurotransmitter receptor trafficking to synapses is altered by the Parkinson's disease VPS35 mutation p.D620N.. Human Molecular Genetics 24(6), pp. 1691-1703. (10.1093/hmg/ddu582)
- Beccano-Kelly, D. A. et al. 2014. LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory.. Human Molecular Genetics 24(5), pp. 1336-1349. (10.1093/hmg/ddu543)
- Beccano-Kelly, D. A. et al. 2014. Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice.. Frontiers in Cellular Neuroscience (10.3389/fncel.2014.00301)
- Vilarino-Guell, C. et al. 2014. DNAJC13 mutations in Parkinson disease.. Human Molecular Genetics 23(7), pp. 1794-1801. (10.1093/hmg/ddt570)
- Brigidi, G. S. et al. 2014. Palmitoylation of δ-catenin by DHHC5 mediates activity-induced synapse plasticity.. Nature Neuroscience 17(4), pp. 522-532. (10.1038/nn.3657)
- Walker, M. D. et al. 2014. Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging. Journal of Parkinson{'}s disease 4(3), pp. 483-498. (10.3233/JPD-140344)
- Doherty, G. H., Beccano-Kelly, D., Yan, S. D., Gunn-Moore, F. J. and Harvey, J. 2012. Leptin prevents hippocampal synaptic disruption and neuronal cell death induced by amyloid β.. Neurobiology of Aging 34(1), pp. 226-237. (10.1016/j.neurobiolaging.2012.08.003)
- Beccano-Kelly, D. and Harvey, J. 2012. Leptin: a novel therapeutic target in Alzheimer's disease?. International Journal of Alzheimer’s Disease 2012, article number: 594137. (10.1155/2012/594137)
- Milligan, C. J. et al. 2009. Robotic multiwell planar patch-clamp for native and primary mammalian cells.. Nature Protocols 4, pp. 244-255. (10.1038/nprot.2008.230)
- Josephs, K. A. et al. 2006. Atypical progressive supranuclear palsy with corticospinal tract degeneration.. Journal of Neuropathology and Experimental Neurology 65(4), pp. 396-405. (10.1097/01.jnen.0000218446.38158.61)